Clinical Trials

72 enrolled

Solid Tumor

NCT06030258 2025-04-30

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

120 enrolled

Thoracic

Small Cell Lung Cancer Extensive Stage

NCT06871527 2025-03-12

Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

44 enrolled

Stomach Neoplasms

NCT05319639 2025-02-27

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

51 enrolled

Stomach Neoplasms

NCT04666688 2025-02-12

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

GastrointestinalGenitourinaryHead & Neck

44 enrolled

Bile Duct Neoplasms, Carcinoma, Transitional Cell, Colonic Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05431270 2025-01-31

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

71 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT03379259 2024-10-26

Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/2 Terminated

39 enrolled 29 charts

Advanced Solid Tumors

NCT03941873 2024-10-26

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

111 enrolled 22 charts

Carcinoma, Carcinoma, Hepatocellular

NCT04068519 2024-10-26

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

300 enrolled 23 charts

Other hematologic neoplasm

Advanced Solid Tumors

NCT06586099 2024-09-19

Tislelizumab with Azacitidine in the Treatment of R/R AML

Phase 1/2 Withdrawn

Leukemia, Myeloid, Acute

NCT06471673 2024-08-26

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

18 enrolled

Breast

Breast Neoplasms

NCT06456138 2024-06-13

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

60 enrolled

Tumor-Agnostic

Neoplasms

NCT06394791 2024-05-01

Evaluation of The Efficacy And Safety of PD-1 + IL-2 Combined With Capox Treatment After Loop Colostomy Surgery in Left-sided Colorectal Cancer Patients Complicating Acute Obstruction

27 enrolled

Left-sided Colorectal Cancer Complicating Acute Obstruction

NCT05842317 2024-02-09

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

60 enrolled

Carcinoma, Hepatocellular

NCT05906524 2024-01-10

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

85 enrolled

Advanced HCC

NCT06022692 2023-09-05

HEAIS001

18 enrolled

Hyperthermia, Digestive System Neoplasms

NCT05982834 2023-08-09

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

43 enrolled

HER2-positive Gastric Cancer

NCT05840835 2023-08-08

IMMINENT-01

60 enrolled

Advanced Solid Tumor

NCT05699811 2023-04-28

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

40 enrolled

Locally Advanced or Metastatic Solid Tumors

NCT05833984 2023-04-27

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

LymphoidOther solid neoplasm

309 enrolled

Solid Tumor

NCT04652440 2023-04-19

Ablation Combined With PD-1 in HCC: Phase II Study

30 enrolled

Carcinoma, Hepatocellular

NCT05746728 2023-04-06

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

45 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04782804 2022-08-18

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

30 enrolled

Cholangiocarcinoma

NCT05394415 2022-05-27

LATE

30 enrolled

Esophageal Squamous Cell Carcinoma

NCT04813107 2022-02-22

ANTICIPATE

79 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT04979663 2021-08-09

GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer

10 enrolled

Biliary Tract Carcinoma

NCT04922047 2021-06-11

TACBIN-01